uMotif
- Company typePrivate
- Founded2012
- HeadquartersLondon, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
uMotif firmographics
Firmographics- Name
- uMotif
- Legal name
- uMotif Limited
- Website
- https://umotif.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
uMotif industry classification
Industry- Product category
- Clinical Trial eCOA/ePRO Software
- NAICS
- Computer Systems Design and Related Services (54151), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (51821)
- SIC
- Services-Computer Programming, Data Processing, Etc. (7370), Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB)
- akta.pro secondary industries
- eConsent & Digital Identity for Trials (HLACAOAE), Wearables & Consumer IoT Integration Platforms (BYOD) (HLACAFAF)
Keywords
Where uMotif is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
uMotif business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Enterprise eCOA/ePRO Platform Licensing: Primary revenue from licensing the eCOA/ePRO and eConsent platform to pharmaceutical sponsors, biotechs, and CROs on a study-by-study basis. Customer logos page indicates relationships ranging from Top 10 Pharma to emerging biotechs. Pricing is quote-based via 'Book a Demo' rather than publicly disclosed.
- Scientific Consulting Services: Launched in May 2026 under CSO Florence Mowlem, providing protocol input, eCOA strategy and implementation consulting, study design and build oversight, expert guidance on migration of complex eCOAs, bespoke diary development, and personalized training modules for sites and participants. Includes COA licensing management and translation services.
- Site Solutions / Site Productivity Add-ons: Additional recurring revenue from eConsent (via ClinOne), Trial Awareness (HCP-targeted newsletters and curated specialist network), Patient Engagement (nudges, content, stipends), and Patient Ride (Uber Health integration). Strengthens patient-site relationship as a platform upsell layer.
- CRO Partnership Revenue (Syneos Health): Through its strategic partnership with Syneos Health, uMotif provides eCOA/ePRO services for Syneos Health customers and co-developed an exclusive patient-centric platform including patient identification, recruitment, eConsent, eDiary, engagement/retention, and payments integrated with StudyKIK.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom quote-based pricing per study |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels9 records
uMotif product offering
Product offeringCore offering
uMotif provides a cloud-native, configurable eCOA/ePRO platform that captures electronic Clinical Outcome Assessments (ePRO, eClinRO, eObsRO, ePerfO) across iOS, Android, and web via provisioned, BYOD, and hybrid device models, delivering >90% compliance in clinical and real-world studies. The core platform is augmented by integrated eConsent (via acquired ClinOne), Patient Engagement, Trial Awareness, Patient Ride (Uber Health), and a Care Cluster Solution, plus a separate Scientific Consulting Services practice offering protocol input, eCOA strategy, and COA licensing management. The platform supports 130+ studies, 35+ therapeutic areas, 35 languages, and is GCP, 21 CFR Part 11, and GDPR compliant with cloud hosting in the US, Europe, and China.
Product overview
uMotif offers a single, modern eCOA/ePRO platform at its core, augmented by a portfolio of integrated modules and services: eConsent, Patient Engagement, Patient Ride (powered by Uber Health), Trial Awareness, the Care Cluster Solution, eDiaries, and Symptom & Drug Tracking. The platform is cloud-native and configured for clinical and real-world studies across all study phases (Phases I–IV) and therapeutic areas, supporting 35+ therapy areas, 130+ studies, and 35 languages. Layered on top of this platform are the new AI-driven MotifAI Assistant capabilities and a separate Scientific Consulting Services offering led by the Chief Scientific Officer that provides protocol input, eCOA strategy, and COA licensing management. The ClinOne site platform (acquired in 2024) extends uMotif's footprint into consent management and site productivity tools. Together these products and modules are designed to strengthen the patient-site relationship and deliver >90% eCOA compliance.
Differentiator
Problem solved
Functional benefit
Brands
- MotifAI Assistant: uMotif's AI-driven automation product deployed across the company's clinical trial technology portfolio to deliver faster, higher-quality clinical trials.
Products and services
- uMotif eCOA/ePRO Platform Cloud-native, configurable and scalable eCOA/ePRO platform capturing electronic Clinical Outcome Assessments (ePRO, eClinRO, eObsRO, ePerfO) across provisioned, BYOD, and hybrid device approaches on mobile, tablet, and web for clinical and real-world studies across all phases (I–IV) and 35+ therapeutic areas.
- eConsent Flexible eConsent and consent management solution for informed onboarding, integrated with telehealth to enhance the participant experience and strengthen the patient-site relationship; built on ClinOne's site platform acquired by uMotif in September 2024.
- Patient Engagement Engagement solutions deployed alongside eCOA or as a standalone offering, including nudges and dynamic alerts, content and educational information, patient stipends, and real-time feedback capture to support all phases of research.
- Patient Ride (with Uber Health) Non-emergency medical transport for trial participants to and from site visits in the United States, delivered via integration with Uber Health, with centralized billing managed by uMotif within the sponsor's study budget to reduce transportation barriers to enrollment.
- Trial Awareness Trial visibility solution for healthcare providers with potentially eligible patients, using a curated referring specialist network, a bi-weekly newsletter, and study-specific landing pages to drive referrals and enrollment.
- Scientific Consulting Services Expert scientific consultation across the lifecycle of clinical trials, including protocol input, study design and COA strategy consulting, eCOA modality consultation, eCOA build oversight, migration/implementation guidance, bespoke diary development, and scale management and translations, available to sponsors and CROs globally.
- Care Cluster Solution Solution enabling data capture from multiple caregivers and participants with clear attribution of exactly who is reporting, particularly valuable in pediatric trials with multiple caregivers, cognitive dysfunction studies, and Parkinson's research where both participant and caregiver perspectives are essential.
Quantifiable outcome
- >90% eCOA compliance in clinical trials and real-world studies
- +5 more outcomes
Companies that use uMotif
Customer profileNamed customers9 records
Segments7 records
Ideal customer profiles5 records
uMotif technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration8 records
AI capability1 record
Feature8 records
uMotif partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered minor, core and flagship.
- XtalksminorCo-hosted free webinar on June 18, 2026 ('Strengthen Participant-Site Readiness for Complex Rare Disease Trials'), featuring speakers from uMotif, Allucent, Empatica, and Accellacare to discuss reducing participant burden, improving site engagement, and leveraging technology for trial execution.
- Critical Path Institute (C-Path)coreMulti-stakeholder collaboration led by uMotif CSO Florence Mowlem PhD on behalf of C-Path, along with co-authors from Top 10 pharma, clinical trial technology providers, and regulators, to produce best-practice recommendations for adopting event-driven eDiaries in clinical trials. The publication was featured in Nature Digital Medicine.
- ClinOneflagshipuMotif acquired ClinOne, a site platform provider, in September 2024 to integrate ClinOne's consent management and site productivity tools with uMotif's eCOA/ePRO platform. The acquisition consolidates a prior strategic partnership and expands uMotif's offerings to include eConsent. Andrea Valente, previously CEO of ClinOne, subsequently became COO and then CEO of uMotif.
- Syneos HealthflagshipStrategic partnership in which Syneos Health (Nasdaq:SYNH) combines its StudyKIK recruitment technology and global biopharma services (across 110+ countries) with uMotif's eCOA/ePRO capabilities to deliver an integrated patient-centric eClinical platform covering patient identification, recruitment, eConsent, eDiary, engagement/retention, and payments.
- Uber HealthcoreIntegration partnership powering uMotif's Patient Ride solution in the United States. Sites use uMotif's online portal to schedule Uber Health rides to/from study visits or approved destinations, with billing centralized and managed by uMotif within the sponsor's study budget to reduce transportation barriers to enrollment.
- IDEOcoreuMotif collaborated with IDEO (the global design firm) to develop and hone its patient-first, human-centered software design approach, which is embedded throughout the eCOA/ePRO platform. IDEO's Executive Design Director Betsy Fields Smith is quoted on the Design Approach page.
- King's College LondoncoreAcademic research collaboration in which King's College London led the EU Innovative Medicines Initiative-funded Hypo-RESOLVE hypoglycemia study using uMotif's eCOA/ePRO platform (10 weeks, 600 participants across UK and Europe; results published in BMJ Open and Diabetic Medicine).
- The Cure Parkinson's TrustcoreResearch collaboration with uMotif, Parkinson's UK, EPDA, Boston Scientific, Cisco, and UCB Pharma on the 100 for Parkinson's multi-nation decentralized study (4,200+ participants across 60 countries, 2.2M+ data points).
- Parkinson's UKcoreResearch collaboration with uMotif and other partners on the 100 for Parkinson's study.
- EPDA (European Parkinson's Disease Association)coreResearch collaboration with uMotif and other partners on the 100 for Parkinson's study.
- Boston ScientificcoreResearch collaboration with uMotif and other partners on the 100 for Parkinson's study.
- CiscocoreResearch collaboration with uMotif and other partners on the 100 for Parkinson's study.
- UCB PharmacoreResearch collaboration with uMotif and other partners on the 100 for Parkinson's study.
Scale indicators10 records
Recent moves6 records
Expansion highlights7 records
uMotif competitors and assessment
Company assessmentBroad incumbents
- Medidata (Dassault Systèmes): Medidata's Rave eCOA is the dominant enterprise eCOA/ePRO platform, integrated with EDC, IRT, and the broader Medidata Clinical Cloud. Directly comparable to uMotif on ePRO/eCOA functionality, but at vastly greater scale and with deeper incumbent sponsor relationships; competes head-to-head for Top 10 pharma contracts.
- Veeva Systems: Veeva Vault eCOA is part of Veeva's broader clinical cloud (Vault CDB, Vault EDC, Vault CTMS). Comparable to uMotif's enterprise eCOA offering but bundled inside a much wider clinical operations platform; competes for global pharma standardization deals.
- IQVIA (eCOA / Patient Cented Solutions): IQVIA's Patient Centric Solutions unit provides eCOA/ePRO alongside EDC, IRT, and CRO services at global scale. Broad incumbent that competes with uMotif for enterprise late-phase trials and offers similar multi-modal patient data capture capabilities.
Direct peers
- Clario: Clario (formerly CRF Health/ERT/Bioclinica) is a leading eCOA vendor with deep scientific and endpoint expertise across clinical trials. Directly competes with uMotif for late-phase, multi-modal eCOA programs and is a recognized Leader in the Everest Group eCOA PEAK Matrix against which uMotif is benchmarked.
- Signant Health: Signant Health (formerly CRF Health/Bracket) provides eCOA, ePRO, and patient-centric clinical trial solutions for pharma sponsors. Direct peer in ePRO/eCOA with comparable patient-experience focus and similar regulatory positioning; named a Leader in the Everest Group eCOA PEAK Matrix assessment.
Emerging players
- Medable: Medable is a decentralized clinical trial platform with eCOA/ePRO capabilities, founded by former uMotif executives' peers (e.g., incoming uMotif CEO Andrea Valente was previously Medable COO). Direct overlap in decentralized ePRO/eCOA use cases, particularly with consumer-friendly BYOD apps; uMotif's incoming CCO James Thatcher also previously led BD at Medable.
- Castor: Castor offers an eClinical platform combining EDC, eCOA, ePRO, and eConsent for academic and commercial trials. Comparable to uMotif's integrated platform vision, particularly following the ClinOne acquisition; positioned as a more affordable alternative for emerging biotechs and academic consortia.
- YPrime: YPrime provides eCOA, IRT, and clinical technology solutions with a focus on configurable, modern patient-facing apps. Direct overlap with uMotif's modern eCOA/ePRO platform and similar focus on UX-driven compliance in mid-to-large clinical trials.
- ObvioHealth: ObvioHealth is a decentralized clinical trial platform offering ePRO, eCOA, telemedicine, and remote patient monitoring. Comparable to uMotif in the decentralized and BYOD-enabled ePRO use case; competes for virtual and hybrid trial sponsors.
- Evinova (AstraZeneca): Evinova is AstraZeneca's digital health unit focused on eCOA, connected devices, and clinical trial solutions. Comparable to uMotif on eCOA/ePRO and adjacent digital health technologies; uMotif's new CCO James Thatcher was previously VP of Business Development at Evinova.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
uMotif social profiles
Digital presenceuMotif compliance and trust
Trust signalCompliance2 records
uMotif financial estimates
Financial estimateRevenue estimate
Valuation estimate
uMotif leadership team
Management profileNumber of profiles
Profiles13 records
uMotif subsidiaries and ownership
Company hierarchySubsidiaries1 record
uMotif funding detail
Funding detailFunding overview
Funding rounds7 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
uMotif M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about uMotif
What does uMotif do?
uMotif provides a cloud-native, configurable eCOA/ePRO platform that captures electronic Clinical Outcome Assessments (ePRO, eClinRO, eObsRO, ePerfO) across iOS, Android, and web via provisioned, BYOD, and hybrid device models, delivering >90% compliance in clinical and real-world studies. The core platform is augmented by integrated eConsent (via acquired ClinOne), Patient Engagement, Trial Awareness, Patient Ride (Uber Health), and a Care Cluster Solution, plus a separate Scientific Consulting Services practice offering protocol input, eCOA strategy, and COA licensing management. The platform supports 130+ studies, 35+ therapeutic areas, 35 languages, and is GCP, 21 CFR Part 11, and GDPR compliant with cloud hosting in the US, Europe, and China.
Is uMotif a public or private company?
uMotif is a private company. It is classified as venture growth investor backed and is currently operating.
When was uMotif founded?
uMotif was founded in 2012. It employs 51 to 100 people.
Where is uMotif based?
uMotif is headquartered in London, United Kingdom, in the Europe region.
How does uMotif make money?
Four revenue lines are on record. Enterprise eCOA/ePRO Platform Licensing is the primary driver. The others are scientific Consulting Services, site Solutions / Site Productivity Add-ons and CRO Partnership Revenue (Syneos Health).
Who are uMotif's main competitors?
Broad incumbents on record are Medidata (Dassault Systèmes), Veeva Systems and IQVIA (eCOA / Patient Cented Solutions). Direct peers are Clario and Signant Health. Emerging players are Medable, Castor, YPrime, ObvioHealth and Evinova (AstraZeneca).
Does uMotif have an API?
No public API is recorded for uMotif.
What industry is uMotif in?
uMotif's product category is Clinical Trial eCOA/ePRO Software. Its primary akta.pro industry code is HLACAOAB, eCOA/ePRO/eDiary & Patient-Facing Data Collection, with a secondary code of HLACAOAE, eConsent & Digital Identity for Trials. Its NAICS code is 54151 and its SIC code is 7370.